Main idea: Triamcinolone acetonide proved to be non-inferior to fluticasone propionate in adult patients with perennial allergic rhinitis; both treatments decreased rhinitis symptoms and showed a good safety profile.
Intranasal sprays are recommended as targeted therapy for allergic rhinitis (AR). Triamcinolone acetonide is a nasal corticosteroid preparation indicated for the treatment of seasonal and perennial allergic rhinitis in different countries worldwide.
In order to determine the efficacy of triamcinolone acetonide in the treatment of PAR, the non-inferiority of triamcinolone acetonide to fluticasone propionate was assessed in Russian adults.
In this randomized, double-blind, parallel-group, multi-center, prospective, non-inferiority, phase III clinical trial, a total of 260 patients with persistent perennial allergic rhinitis were randomized to receive either triamcinolone acetonide or fluticasone propionate nasal sprays for 4 weeks.
Results: The rhinitis symptoms decreased significantly at the end of study treatment (day 28) in both groups: -8.2 ± 3.0 in the triamcinolone acetonide arm versus -8.0 ± 2.8 in the fluticasone propionate arm. The mean difference between the groups (triamcinolone acetonide – fluticasone propionate) for rhinitis symptoms change from baseline was -0.2. Triamcinolone acetonide was well tolerated with no difference in adverse event occurrence compared with fluticasone propionate.